Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Epigenetic silencing including histone modifications and DNA methylation is an important tumorigenic mechanism. However, its role in cancer immunopathology and immunotherapy is poorly understood. Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, and subsequently determine effector T-cell trafficking to the tumour microenvironment. Treatment with epigenetic modulators removes the repression and increases effector T-cell tumour infiltration, slows down tumour progression, and improves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) checkpoint blockade and adoptive T-cell transfusion in tumour-bearing mice. Moreover, tumour EZH2 and DNMT1 are negatively associated with tumour-infiltrating CD8(+) T cells and patient outcome. Thus, epigenetic silencing of TH1-type chemokines is a novel immune-evasion mechanism of tumours. Selective epigenetic reprogramming alters the T-cell landscape in cancer and may enhance the clinical efficacy of cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epigenetic reprogramming with shRNAs targeting DNA methyltransferase 1 (DNMT1) or pan-DNMT blockers like decitabine and guadecitabine has been shown to resemble EZH2 inhibition in its capacity to promote CXCL9 and CXCL10 secretion in various models of breast, lung, and ovarian carcinoma”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [107]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The mTOR pathway has long been recognized to play a pivotal role in integrating signals at the cellular level and promote autoimmunity and carcinogenesis18,19.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“and TH1 cytokines”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Cited by
Items 401–500 of 1,000
Dong, H., Liu, S., Zhang, X., Chen, S., Kang, L., Chen, Y., Ma, S., Fu, X., Liu, Y., Zhang, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0428 · Cited by 55
“In support our studies, previous reports show that PRC2 components and H3K27me3-mediated the TH1-type chemokine gene silencing in ovarian and colon cells (40, 43).”
ResultNing, H., HUANG, S. H., Yang, L., Zhi, R., Yan, H., Jin, J., Hu, Z., Guo, K., Liu, J., Yang, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34253-1 · Cited by 58
Emerging Epigenetic‐Based Nanotechnology for Cancer Therapy: Modulating the Tumor Microenvironment
Zhang, J., Huang, L., Ge, G., & Hu, K. (2023) · Advanced Science · doi:10.1002/advs.202206169 · Cited by 63
Qiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z., & Xie, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105490 · Cited by 59
“Epigenetic silencing of the tumor Th1-type chemokines CXCL9 and CXCL10 also contributes to severe T-cell infiltration and greater tumor evasion [53].”
BackgroundThe epigenetic hallmarks of immune cells in cancer
Yu, J. H., Xiao, C., Fan, T. T., Deng, Z., Wang, D., Cai, W., Li, J., Liao, T., Li, C., & He, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02255-4 · Cited by 62
Precision medicine driven by cancer systems biology
Filipp, F. V. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9662-4 · Cited by 59
“An in vitro EZH2 drug targeting assay made it possible to validate genes associated with immune recognition, cytokine, chemokine, and major histocompatibility complex class II antigen presentation [85, 113].”
MethodYahata, T., Mizoguchi, M., Kimura, A., Orimo, T., Toujima, S., Kuninaka, Y., Nosaka, M., Ishida, Y., Sasaki, I., Fukuda‐Ohta, Y., et al. (2019) · Cancer Science · doi:10.1111/cas.13958 · Cited by 57
Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities
Tien, F., Lu, H., Lin, S., & Tsai, H.-C. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-022-00893-0 · Cited by 55
Cheng, H., Ge, X., Zhuo, S., Gao, Y., Zhu, B., Zhang, J., Shang, W., Xu, D., Ge, W., & Shi, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01413 · Cited by 52
“The finding was congruent with the recent report that Th1 chemokines were susceptible to the EZH2-mediated epigenetic regulation (Peng et al., 2015) and the co-treatment likely caused the de-repression of chemokines from EZH2-dependent restraint by suppressing its expression.”
ResultDrugging histone methyltransferases in cancer
Richart, L., & Margueron, R. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.009 · Cited by 51
Considerations for the delivery of STING ligands in cancer immunotherapy
Petrovic, M., Borchard, G., & Jordan, O. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.033 · Cited by 52
Yang, Z., Xu, F., Wang, H., Teschendorff, A. E., Xie, F., & He, Y. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103399 · Cited by 57
“The important role of epigenetics in determine immunity and immune therapy for cancers has been well demonstrated [90].”
BackgroundUSP15 suppresses tumor immunity via deubiquitylation and inactivation of TET2
Chen, L., Smith, M. D., Lv, L., Nakagawa, T., Li, Z., Sun, S., Brown, N. G., Xiong, Y., & Xu, Y. (2020) · Science Advances · doi:10.1126/sciadv.abc9730 · Cited by 54
Guo, W., Wang, Y., Yang, M., Wang, Z., Wang, Y., Chaurasia, S., Wu, Z., Zhang, M., Yadav, G. S., Rathod, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb3555 · Cited by 53
“More-over, a recent study has also shown that EZH2 can epigenetically silence chemokine CXCL10 expression in tumor cells and results in the suppression of T cell infiltration ( 40 ).”
InfluentialHan, Y., Xu, S., Ye, W., Wang, Y., Zhang, X., Deng, J., Zhang, Z., Liu, L., & Liu, S. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04297-0 · Cited by 52
GPI Is a Prognostic Biomarker and Correlates With Immune Infiltrates in Lung Adenocarcinoma
Han, J., Deng, X., Sun, R., Luo, M., Liang, M., Gu, B., Zhang, T., Peng, Z., Lu, Y., Tian, C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.752642 · Cited by 56
“The inflammatory receptor CCR4 promotes the respiratory burst and phagocytosis of macrophages (43) and controls the differentiation of M1/M2 macrophages (44).”
BackgroundDual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
Spiliopoulou, P., Spear, S., Mirza, H., Garner, I., McGarry, L., Freile, F. G., Cheng, Z., Ennis, D. P., Iyer, N., McNamara, S., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0743 · Cited by 51
“HGSC cells can evade immune responses by altering their epigenome, and targeting ovarian cancer epigenetics can reactivate cancer testis antigens (3), induce viral mimicry (4), and alter the tumor immune microenvironment and immune cell function (5).”
Epigenetic Regulation: A Link between Inflammation and Carcinogenesis
Vezzani, B., Carinci, M., Previati, M., Giacovazzi, S., Sala, M. D., Gafà, R., Lanza, G., Wieckowski, M. R., Pinton, P., & Giorgi, C. (2022) · Cancers · doi:10.3390/cancers14051221 · Cited by 55
BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy
Samanta, D., Huang, T. Y.-T., Shah, R., Yang, Y., Pan, F., & Semenza, G. L. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108073 · Cited by 49
Hoffmann, F., Niebel, D., Aymans, P., Ferring‐Schmitt, S., Dietrich, D., & Landsberg, J. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-0818-7 · Cited by 51
T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review
Wu, J., Dand, S., Doig, L., Papenfuss, A. T., Scott, C. L., Ho, G., & Ooi, J. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672502 · Cited by 57
“These include the expression of endothelin B receptor (34) and Fas ligand (35) within the tumor endothelium, elevated levels of vascular endothelial growth factors (VEGF) which are commonly seen in HGSOC (36), and the presence of epigenetic silencing of Th1-type chemokines (37).”
BackgroundProtein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy
Dai, W., Zhang, J., Li, S., He, F., Liu, Q., Gong, J., Yang, Z., Gong, Y. Q., Tang, F., Wang, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.865964 · Cited by 52
“Therefore, epigenetic modulator treatments can eliminate this suppression and ultimately enhance cancer treatment (55).”
BackgroundJiang, P., Zhang, Z., Hu, Y., Liang, Z., Han, Y., Li, X., Zeng, X., Zhang, H., Zhu, M., Dong, J. W., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01676-0 · Cited by 53
“This was consistent with previous studies showing that DNMT1 can silence the immune response of Th1 cells through epigenetic silencing [27].”
Applications of chemokines as adjuvants for vaccine immunotherapy
Mohan, T., Zhu, W. S., Wang, Y., & Wang, B. (2017) · Immunobiology · doi:10.1016/j.imbio.2017.12.001 · Cited by 51
Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy
Pérez‐Romero, K., Rodríguez, R. M. A., Amedei, A., Barceló‐Coblijn, G., & Lopez, D. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155521 · Cited by 52
“In these tumors, the use of demethylating agents can restore chemokine production, enhancing T cell recruitment to the tumor site [82].”
BackgroundIoannou, N., Hagner, P. R., Stokes, M., Gandhi, A. K., Apollonio, B., Fanous, M., Papazoglou, D., Sutton, L., Rosenquist, R., Amini, R., et al. (2020) · Blood · doi:10.1182/blood.2020006073 · Cited by 51
Li, X., Wang, F., Xu, X., Zhang, J., & Xu, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.636595 · Cited by 51
The Role of the Microbiome in Pancreatic Cancer
Miyabayashi, K., Ijichi, H., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184479 · Cited by 53
CCRK is a novel signalling hub exploitable in cancer immunotherapy
Mok, M. T. S., Zhou, J., Tang, W., Zeng, X., Oliver, A. W., Ward, S. E., & Cheng, A. S. L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.008 · Cited by 53
“, in press), at least three other pathways in the CCRK circuit have been recently demonstrated to exert tumor-immune escape functions: 1) β-catenin hyper-activity in melanoma contributes to T cell exclusion from tumor microenvironment via suppression of dendritic cell recruitment (Spranger, Bao, & Gajewski, 2015); 2)…”
Lu, T., Wang, S., Xu, L., Zhou, Q., Singla, N., Gao, J., Manna, S., Pop, L., Xie, Z., Chen, M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz3199 · Cited by 48
EZH2 as a Regulator of CD8+ T Cell Fate and Function
Stairiker, C. J., Thomas, G. D., & Salek‐Ardakani, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.593203 · Cited by 53
“These antitumor effects were attributed to increased expression of genes associated withMHCI peptide processing and presentation and increased expression of T cell-recruiting chemokines Cxcl9 and Cxcl10 (48, 50, 51).”
BackgroundZhou, M., Yuan, J., Deng, Y., Fan, X., & Shen, J. (2021) · Oncogenesis · doi:10.1038/s41389-020-00296-6 · Cited by 49
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 51
Self-citationXu, Y., Li, P., Liu, Y., Xin, D., Lei, W., Liang, A., Han, W., & Qian, W. (2022) · 癌症:英文版 · doi:10.1002/cac2.12313 · Cited by 49
“Additionally, ERV-independent activation is seen in several IFN-responsive genes, such as CXC-chemokine ligand 9 (CXCL9) and CXCL10, which are directly regulated by DNA methylation and histone modifications [60, 61].”
BackgroundHuang, S., Chung, J. Y., Li, C., Wu, Y., Qiao, G., To, K., & Tang, P. M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217272 · Cited by 49
Huang, C.-X., Lao, X., Wang, X., Ren, Y.-Z., Lu, Y., Shi, W., Wang, Y., Wu, C.-Y., Xu, L., Chen, M.-S., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.10.012 · Cited by 56
Wu, J., Tang, Q., Yang, L., Chen, Y., Zheng, F., & Hann, S. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-00626-6 · Cited by 47
SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications
Fukumoto, T., Magno, E., & Zhang, R. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0368 · Cited by 49
“EZH2 inhibition will not only induce synthetic lethality in ovarian tumor cells with ARID1A mutation, SMARCA4 mutation, or CARM1 amplification, but also enhance the recruitment of cytotoxic T cells to the tumor microenvironment (42).”
BackgroundResistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
Zhuang, Y., Liu, C. X., Liu, J., & Li, G. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s239398 · Cited by 50
“The use of Hypomethylating agents (HMAs) reduces the inhibition of chemokines and increases TILs, thereby increasing the therapeutic effect of PD-1/PD-L1 blockade.(32)”
BackgroundImmunogenomic cancer evolution: A framework to understand cancer immunosuppression
Kumagai, S., Momoi, Y., & Nishikawa, H. (2025) · Science Immunology · doi:10.1126/sciimmunol.abo5570 · Cited by 53
Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors
Bronger, H., Magdolen, V., Goettig, P., & Dreyer, T. F. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09807-3 · Cited by 51
The Network of Cytokines in Brain Metastases
Fares, J., Cordero, Á., Kanojia, D., & Lesniak, M. S. (2021) · Cancers · doi:10.3390/cancers13010142 · Cited by 47
Seier, J. A., Reinhardt, J., Saraf, K., Ng, S. S., Layer, J. P., Corvino, D., Althoff, K., Giordano, F. A., Schramm, A. R., Fischer, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001335 · Cited by 50
Reversing Post-Infectious Epigenetic-Mediated Immune Suppression
Abhimanyu, A., Ontiveros, C. O., Guerra-Resendez, R. S., Nishiguchi, T., Ladki, M., Hilton, I. B., Schlesinger, L. S., & DiNardo, A. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.688132 · Cited by 47
Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy
Afolabi, L. O., Afolabi, M. O., Sani, M. M., Okunowo, W. O., Yan, D., Chen, L., Zhang, Y., & Wan, X. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1286 · Cited by 39
B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments
Yuan, W., Huang, C.-X., Xiao, C., Chen, D., Shan, H., He, H., & Kuang, D. (2021) · Oncogene · doi:10.1038/s41388-021-01918-y · Cited by 47
“Of note, malignant cells lose the capability to express these chemokines due to epigenetic alterations [73].”
BackgroundChu, L., Qu, Y.-X., An, Y., Hou, L., Li, J., Li, W., Fan, G., Song, B., Li, E., Zhang, L., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04601-6 · Cited by 52
“T helper 1-type chemokines CXCL9 and CXCL10 are silenced by PRC2 in ovarian and colon cancer [62, 63].”
BackgroundZhang, J., Zhang, H., Ding, X., Hu, J., Li, Y., Zhang, J., Wang, H., Qi, S., Xie, A., Shi, J., et al. (2022) · Theranostics · doi:10.7150/thno.69494 · Cited by 49
“For instance, EZH2, a histone 3 lysine 27 trimethylation regulator, mediates epigenetic silencing of tumor CXCL9 and CXCL10, two Th1-type chemokines, and consequently represses effector T cell trafficking into the tumor microenvironment [47].”
BackgroundNCOA3 impairs the efficacy of anti-PD-L1 therapy via HSP90α/EZH2/CXCL9 axis in colon cancer
Liu, J., Su, Y., Zhang, C., Dong, H., Yu, R., Yang, X., Tian, Y., Feng, Y., Zhang, J., Shi, M., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114579 · Cited by 47
Targeting the epigenome in malignant pleural mesothelioma
McLoughlin, K. C., Kaufman, A. S., & Schrump, D. S. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.06.06 · Cited by 47
“Observations that combined decitabine/GSK126 or 5-AZA/entinostat treatment markedly augment efficacy of adoptively transferred CTL or anti-PD-L1 via up-regulation of Th1 signaling and inhibition of immunosuppressive myeloid derived suppressor cells within the tumor microenvironment in murine cancer models (113,135) su…”
BackgroundRegulation of cancer immune escape: The roles of miRNAs in immune checkpoint proteins
Yang, Q., Cao, W., Wang, Z., Zhang, B., & Liu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.015 · Cited by 46
Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies
Hammerl, D., Rieder, D., Martens, J. W. M., Trajanoski, Z., & Debets, R. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.09.004 · Cited by 51
Obstacles to T cell migration in the tumor microenvironment
Nicolas-Boluda, A., & Donnadieu, E. (2019) · Comparative Immunology, Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2018.12.006 · Cited by 43
Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
Haibe, Y., Husseini, Z. E., Sayed, R. E., & Shamseddine, A. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176176 · Cited by 47
“Ezh2 aids in downregulating Th1-type chemokines that subsequently decrease cytotoxic T-cell tumor infiltration [115].”
BackgroundCui, Y., Miao, Y., Cao, L., Guo, L., Cui, Y., Yan, C., Zeng, Z., Xu, M., & Han, T. (2023) · Nature Communications · doi:10.1038/s41467-023-41101-3 · Cited by 45
“The signaling properties of GPCRs are de fi ned by coupling to one of four class of G α proteins (G α s, G α i/o, G α q/11, and G α 12/13), which bind to and stimulate their cognate downstream effectors to mediate GPCR signaling 19 .”
Santana-Hernández, S., Suárez-Olmos, J., Servitja, S., Berenguer‐Molins, P., Costa-García, M., Comerma, L., Rea, A., Perera‐Bel, J., Menéndez, S., Arpí, O., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02918-4 · Cited by 49
Chomiak, A. A., Tiedemann, R. L., Liu, Y., Kong, X., Cui, Y., Wiseman, A. K., Thurlow, K. E., Cornett, E. M., Topper, M. J., Baylin, S. B., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk4423 · Cited by 48
Epigenetic regulators combined with tumour immunotherapy: current status and perspectives
Zhang, H., Pang, Y., Yi, L., Wang, X., Wei, P., Wang, H., & Lin, S. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01856-6 · Cited by 45
“GSK126 inhibited EZH2 and simultaneously promoted the development of MDSCs [138, 139].”
CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes
Aznar, M. A., Labiano, S., Díaz‐Lagares, Á., Molina, C., Garasa, S., Azpilikueta, A., Etxeberría, I., Sánchez-Paulete, A. R., Korman, A. J., Esteller, M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0159 · Cited by 44
“In fact, modification of DNA-methylation affects genes relevant for Th1 biology in vivo (53).”
BackgroundChabanon, R. M., Morel, D., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.018 · Cited by 47
Targeted Delivery of CXCL9 and OX40L by Mesenchymal Stem Cells Elicits Potent Antitumor Immunity
Yin, P., Gui, L., Wang, C., Yan, J., Liu, M., Ji, L., Wang, Y., Ma, B., & Gao, W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.08.005 · Cited by 47
NPM1 inhibits tumoral antigen presentation to promote immune evasion and tumor progression
Wang, X., Chai, Y., Quan, Y., Wang, J., Song, J., Zhou, W., Xu, X., Xu, H., Wang, B., & Cao, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01618-6 · Cited by 51
“Altered immune cell composition [30–32], innate immune sensing pathways [33, 34], cellular metabolism [35–37] and epigenetic factors [6, 38, 39] are involved in modulating the TME.”
BackgroundUSP44 Promotes the Tumorigenesis of Prostate Cancer Cells through EZH2 Protein Stabilization.
Park, J. M., Lee, J. E., Park, C. M., & Kim, J. H. (2019) · PubMed Central · doi:10.14348/molcells.2018.0329 · Cited by 46
Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy
Hirukawa, A., Singh, S., Wang, J., Rennhack, J. P., Swiatnicki, M., Sanguin-Gendreau, V., Zuo, D., Daldoul, K., Lavoie, C., Park, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.105 · Cited by 41
Wang, X., Brea, L. T., & Yu, J. (2019) · PubMed · Cited by 45
Eckert, E. C., Nace, R. A., Tonne, J. M., Evgin, L., Vile, R. G., & Russell, S. J. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.12.003 · Cited by 44
New directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry
Maryamchik, E., Gallagher, K., Preffer, F. I., Kadauke, S., & Maus, M. V. (2020) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21880 · Cited by 46
“…expression or prevent deactivation of chemokines, such as CCL5, CCL2, or CXCL9/10, result in improved T cell recruitment and better tumor control (Barreira da Silva et al., 2015; Hong et al., 2011; Molon et al., 2011; Nishina et al., 2019; Peng et al., 2015; Qin et al., 2019; Uehara et al., 2017).”
BackgroundEpigenetics and CD8+ T cell memory*
Montacchiesi, G., & Pace, L. (2021) · Immunological Reviews · doi:10.1111/imr.13057 · Cited by 46
Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis
Suk, K. T., Mederacke, I., Gwak, G., Cho, S. W., Adeyemi, A., Friedman, R. A., & Schwabe, R. F. (2016) · Gut · doi:10.1136/gutjnl-2015-310212 · Cited by 50
Liang, Y. J., Wang, L., Ma, P., Ju, D., Zhao, M., & Shi, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1308264 · Cited by 44
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
Jenkins, R. W., Thummalapalli, R., Carter, J., Cañadas, I., & Barbie, D. A. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-060116-022926 · Cited by 44
DNA Methylation–Targeted Drugs
Costa, E. M. D., McInnes, G., Beaudry, A., & Raynal, N. J. ‐. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000278 · Cited by 46
Renaude, E., Kroemer, M., Loyon, R., Binda, D., Borg, C., Boyer‐Guittaut, M., Hervouet, É., & Peixoto, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051673 · Cited by 45
“These studies highlighted the importance of DNA and histone methylation in the epigenetic regulation of the main antitumor immune cells, including Th1 and CD8 T cells, into the tumor microenvironment [68,69].”
BackgroundTargeting DNA methyltransferases in non-small-cell lung cancer
Al-Yozbaki, M., Jabre, I., Syed, N. H., & Wilson, C. M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.01.005 · Cited by 43
NEFM DNA methylation correlates with immune infiltration and survival in breast cancer
Li, D., Zhao, W., Zhang, X., Lv, H., Li, C., & Sun, L. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01096-4 · Cited by 47
“KMT3A (SETD2), a methyltransferase, is required for interferon pathway by catalyzing the methylation of STAT1, a key transcription factor of interferon response [52].”
BackgroundIntimate communications within the tumor microenvironment: stromal factors function as an orchestra
Cheng, B., Yu, Q., & Wang, W. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-022-00894-z · Cited by 50
“Tumor production of CXCL9 and CXCL10, which are Th1-type chemokines, can be repressed by either enhancer of zeste homolog 2 (EZH2, a core of the PRC2 complex)-mediated histone H3 lysine 27 trimethylation or DNA methyltransferase 1 (DNMT1)-induced DNA methylation, subsequently resulting in less recruitment of IFN-γ-pro…”
BackgroundSelf-citationEpigenetics: Mechanisms, potential roles, and therapeutic strategies in cancer progression
Wang, D., Zhang, Y., Li, Q., Li, Y., Li, W., Zhang, A., Xu, J., Meng, J., Tang, L., & Lyu, S. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.04.040 · Cited by 56
“54 In addition, polycomb repressive complex 2-mediated epigenetic silencing of Th1-type chemokines inhibits effector T cell trafficking in colon cancer.”
Song, Y., Xu, Y., Zhu, X., Fu, J., Deng, C., Chen, H., Xu, H., Song, G., Lu, J., Tang, Q., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01198 · Cited by 44
“As CD4 and IFNGR2 together contribute to the activation of Th1 cells (45), and M1 macrophages are characterized by CD68, we were able to validate the correlation of these immune signatures (Figures 4D, 6A).”
BackgroundKarin, N. (2021) · Cancers · doi:10.3390/cancers13246317 · Cited by 45
Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours
White, L. G., Goy, H. E., Rose, A. J., & McLellan, A. D. (2022) · Cancers · doi:10.3390/cancers14040978 · Cited by 43
“The expression of other CXCR3 ligands, CXCL9 and CXCL10, has been shown to be epigenetically repressed in colon and ovarian tumour cells via DNA methylation and the H3K27me3 activity of the polycomb repressive complex 2 [49,50].”
BackgroundZheng, P., Li, N., & Zhan, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.972341 · Cited by 45
“Further, EZH2 in combination with DNMT1 had a negative correlation with CD8+ T cells tumor infiltration and prognosis of OC patients (34).”
BackgroundYin, J., Gu, T., Chaudhry, N. Y., Davidson, N. E., & Huang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1325615 · Cited by 46
Chemokine Heterocomplexes and Cancer: A Novel Chapter to Be Written in Tumor Immunity
D’Agostino, G., Cecchinato, V., & Uguccioni, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02185 · Cited by 42
Miyahira, A. K., Sharp, A., Ellis, L., Jones, J. C., Kaochar, S., Larman, H. B., Quigley, D. A., Ye, H., Simons, J. W., Pienta, K. J., et al. (2019) · The Prostate · doi:10.1002/pros.23934 · Cited by 42
PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL
Andrieu, G. P., Kohn, M., Simonin, M., Smith, C. L., Cieślak, A., Dourthe, M.-É., Charbonnier, G., Graux, C., Huguet, F., Lhéritier, V., et al. (2021) · Blood · doi:10.1182/blood.2020010081 · Cited by 44
Epigenetic Reprogramming of CD4+ Helper T Cells as a Strategy to Improve Anticancer Immunotherapy
Renaude, E., Kroemer, M., Borg, C., Peixoto, P., Hervouet, É., Loyon, R., & Adotévi, O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669992 · Cited by 46
“Inhibition of EZH2 and DNMT1 by chemical inhibitors restored the expression of CXCL9 and CXCL10 and increased effector T cell tumor infiltration (85).”
BackgroundInhibition of DNMT1 potentiates antitumor immunity in oral squamous cell carcinoma
Yang, S., Wang, W., Zhou, J., Wu, L., Zhang, M.-J., Yang, Q., Deng, W., & Sun, Z. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109113 · Cited by 45
Self-citationZhang, P., Du, Y., Bai, H., Wang, Z., Duan, J., Wang, X., Zhong, J. Y., Wan, R., Xu, J., He, X., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02598-5 · Cited by 43
Li, J., Zhao, Q., Zhang, N., Wu, L., Wang, Q., Li, J., Pan, Q., Pu, Y., Luo, K., Gu, Z., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c02337 · Cited by 43
Integration of Nano drug-delivery System With Cancer Immunotherapy
Nakamura, T., & Harashima, H. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0071 · Cited by 40
Regulation of T cell differentiation and function by epigenetic modification enzymes
Liu, H., Li, P., Wei, Z., Zhang, C., Xia, M., Du, Q., Chen, Y., Liu, N., Li, H., & Yang, X. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00731-w · Cited by 40
Guo, B., Tan, X., & Cen, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242191 · Cited by 43
“reported that treatment with an inhibitor of EZH2 together with an inhibitor of DNA methyltransferase 1 (DNMT1) led to better tumor growth suppression than either approach alone in ovarian tumor-bearing mice [10, 11].”
BackgroundGrunewald, C. M., Haist, C., König, C., Petzsch, P., Bister, A., Nößner, E., Wiek, C., Scheckenbach, K., Köhrer, K., Niegisch, G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.782448 · Cited by 39
“, the induction of chemokines like CXCL9 and -10, thereby promoting T-cell infiltration (52), or via the decrease of immunosuppressive cells in the microenvironment like myeloid-derived suppressor cells (MDSCs) (53).”
BackgroundSamaržija, I., Tomljanović, M., Kujundžić, R. N., & Gall‐Tros̆elj, K. (2022) · Cancers · doi:10.3390/cancers14194761 · Cited by 39
Vienot, A., Pallandre, J., Renaude, E., Viot, J., Bouard, A., Spehner, L., Kroemer, M., Abdeljaoued, S., van der Woning, B., de Haard, H., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2144669 · Cited by 40
“sive H3K9me3 or H3K27me3, resulting in chromatin modification and CXCL9/10 gene re-expression in fibroblasts.(29,30) G9a and EZH2 inhibition, using chemical inhibitors or siRNA, restored CXCL9/10 expressions, preventing the effect of TGF-β1 on the epigenetic silencing of these chemokines (Figures 6c-d).”
BackgroundPolycomb Directed Cell Fate Decisions in Development and Cancer
German, B., & Ellis, L. (2022) · Epigenomes · doi:10.3390/epigenomes6030028 · Cited by 37
Mao, J., Li, J., Chen, J., Wen, Q., Cao, M., Zhang, F., Li, B., Zhang, Q., Wang, Z., Zhang, J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007481 · Cited by 46
Stoll, G., Pol, J. G., Soumelis, V., Zitvogel, L., & Kroemer, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1484980 · Cited by 42
Defining Immunogenic and Radioimmunogenic Tumors
Medler, T. R., Blair, T. C., Crittenden, M. R., & Gough, M. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.667075 · Cited by 40
Tissues and Tumor Microenvironment (TME) in 3D: Models to Shed Light on Immunosuppression in Cancer
Ho, T., & Msallam, R. (2021) · Cells · doi:10.3390/cells10040831 · Cited by 39
Metadata
- Authors
- Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., Kotarski, J., Tarkowski, R., Dou, Y., Cho, K., Hensley-Alford, S., Munkarah, A., Liu, R., & Zou, W.
- Affiliations
- University of Michigan (US)
- Medical University of Lublin (PL)
- Henry Ford Health (US)
- Corresponding author
- Zou, Weiping
- ORCID
- Venue
- Nature
- Published
- 2015-10-26
- Volume
- 527
- Issue
- 7577
- Pages
- 249-253
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4779053
- OpenAlex
- W2103021272
- Cited by
- 1,201
- References
- 37
- Citations by year
- 2026: 79 · 2025: 100 · 2024: 104 · 2023: 132 · 2022: 155 · 2021: 159 · 2020: 125 · 2019: 109 · 2018: 85 · 2017: 89 · 2016: 61 · 2015: 2
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (CA099985, R01CA123088, R01CA152470, CA193136, R01CA156685, CA123088, 5P30 CA 46592, CA156685, CA152470, R01CA171306, R01CA193136, CA171306, R01CA099985, F31CA189440, R01CA190176, CA190176, P30CA046592)
- National Institute of General Medical Sciences (R01GM082856)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- epigenetic silencing, EZH2, DNMT1, CXCL9, CXCL10, ovarian cancer, tumor immunosuppression, adoptive T cell therapy, CD8+ T cells, H3K27me3, DNA methylation, histone modifications, tumor microenvironment, immunotherapy response
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, DNA (Cytosine-5-)-Methyltransferase 1, Animals, DNA (Cytosine-5-)-Methyltransferases, Female, Histones, Humans, Immunotherapy, Lysine, Ovarian Neoplasms, Prognosis, Tumor Cells, Cultured, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Th1 Cells, Chemokines, Tumor Escape, DNA Methylation, Gene Silencing, Xenograft Model Antitumor Assays, Epigenesis, Genetic, Mice, Chemokine CXCL10, Chemokine CXCL9, B7-H1 Antigen, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.